Adial Pharmaceuticals ADIL
NASDAQ ADIL
$4.12 -0.01 (-0.24%)
At close: Oct 2, 2026 · 4:00 PM EDT

Adial Pharmaceuticals (ADIL) Income from Discontinued Operations (2022 - 2023)

Updated

Adial Pharmaceuticals (ADIL) reported Income from Discontinued Operations of -$15,896 for Q4 2023.

Analysis

Adial Pharmaceuticals (ADIL) Income from Discontinued Operations (2022 - 2023) Analysis & Trends

For FY2023, Adial Pharmaceuticals posted Income from Discontinued Operations of $1.88 million.

  • By year, Income from Discontinued Operations came in at -$1.94 million in FY2022.
  • Five-year quarterly Income from Discontinued Operations spans a low of -$665,953 in Q1 2023 and a high of $2.6 million in Q2 2023.
  • Per Business Quant data, the three quarters before Q4 2023 came in at -$37,276 (Q3 2023), $2.6 million (Q2 2023) and -$665,953 (Q1 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn -
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn -
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn -
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn -
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 8.00 Mn
10 Adial Pharmaceuticals 19.04 Mn 19.04 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -15,896.00
Sep 30, 2023 -37,276.00
Jun 30, 2023 2.60 Mn
Mar 31, 2023 -665,953.00
Jun 30, 2022 -610,652.00
API Access

Adial Pharmaceuticals Income from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-discontinued-operations&ticker=ADIL&period=max&api_key=YOUR_API_KEY